Search | Médecins Sans Frontières Access Campaign

241 results found
There are 2 active filters
Clear all filters
Georgia
India

241 results found

6th October 2010: Wednesday in New Delhi, patients and activists stage a DIE-IN to protest at talks today between the European Union and the Indian government over a free trade agreement that could end production of life-saving affordable medicines for millions in need in developing countries.

Press release |

12 March 2024

MSF response to signing of EFTA-India trade agreement

Certain clauses in the trade deal could dilute use of public health measures under Indian patent law.

Tags Intellectual property and trade free trade agreementTRIPS SwitzerlandIndia

Thousands of demonstrators took to the streets in Delhi once again on 2 March 2011, in protest over the planned Free Trade Agreement between India and the European Union (EU) which will restrict access to life-saving medicines.Thousands of demonstrators took to the streets in Delhi once again on 2 March in protest over the planned Free Trade Agreement between India and the European Union (EU) which will restrict access to life-saving medicines.

Technical brief |

12 March 2024

MSF Comments on intellectual property provisions in the final agreement of India-EFTA Agreement

MSF technical analysis shares problematic clauses in EFTA India FTA trade agreement

Tags Intellectual property and trade free trade agreement SwitzerlandIndia

Press release |

15 February 2024

MSF welcomes Indian government standing strong against EFTA trade deal’s harmful intellectual property provisions

MSF welcomes the Indian Commerce Ministry’s strong stand against the inclusion of data exclusivity in its free trade agreement talks with the European Free Trade Association (EFTA).

Tags Intellectual property and trade India

Press release |

14 February 2024

Millions of peoples’ access to affordable medicines at risk if India-EFTA trade deal finalised as is

Leaked text shows India-EFTA trade deal includes excessive intellectual property provisions that may require India to gut pro-public health national laws, which may undermine people's access to affordable medicines from India

Tags Intellectual property and trade European Free Trade Association India

MSF Doctor Joan providing a consultation to Nischaya, an XDR-TB patient, in the MSF clinic in Mumbai.

Press release |

23 March 2023

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson India

A pharmacist unpacks medications at the mobile clinic pharmacy. Through mobile clinics, MSF provides medical services to local populations.

Press release |

14 March 2023

News Update: EU-India FTA negotiations could have negative impact on access to medicines

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

Tags Intellectual property and trade free trade agreement European CommissionEuropean Free Trade Association United KingdomIndiaEuropean Union

Press release |

16 January 2023

India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Tags Tuberculosis tuberculosis bedaquiline patent opposition World Health Organization India

XDR-TB patient Hanif, during his weekly consultation with Dr. Joan, at MSF’s clinic in Mumbai.

Press release |

02 November 2022

MSF responds to UK's disastrous proposal on intellectual property in UK-India Free Trade Agreement

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

Tags Intellectual property and trade TRIPS WTO United KingdomIndia

Hanif is 25 years old, lives in Mumbai, and is one of only a handful of extensively drug-resistant TB (XDR-TB) patients in India lucky enough to be able to have acesss to the new drugs. After having failed treatment for the fourth time, Hanif was referred to the clinic of Medecins Sans Frontieres (MSF) / Doctors Without Borders, an international medical humanitarian organisation who since 2006 provides free diagnosis, treatment and support to patients with drug-resistant TB in Mumbai.

Press release |

01 May 2020

MSF responds to USTR 2020 Special 301 Report

Amidst the ongoing global crisis caused by the COVID-19 pandemic, the United States Trade Representative (USTR) released its annual “Special 301 Report” targeting countries for implementing and supporting public health safeguard in ...

Tags Intellectual property and trade United States of AmericaIndia

Statement |

07 February 2020

MSF submission to USTR 2020 Special 301 Report review process

The USTR called for comments from stakeholders for their 2020 Special 301 Report. The Special 301 Report is an annual report by the USTR that names countries on "watch lists" in line with its powerful pharmaceutical industry's demands ...

Tags Intellectual property and trade United States of AmericaIndia

So called “orange pills” (Amoxicillin), an antibiotic very popular among patients in Ahmed Shah Baba hospital in Kabul. Photograph by Doris Burtscher

Opinion article |

21 November 2019

World Antibiotic Awareness Week: Lack of access

Shortages of first-line antibiotics, which are essential to treat a wide range of common infections, are a major public health threat

Tags Antimicrobial resistance India

Speech |

30 October 2019

Nandita Venkatesan's speech at the 50th Union World Conference on Lung Health

Tags Tuberculosis tuberculosis pretomanidbedaquilinedelamanid Union Conference on Lung Health J&J Can you hear us? India

Press release |

23 September 2019

MSF urges PM Modi not to make any trade commitments to US threatening access to medicines

“India should be cautious while signing any trade package or launching trade negotiations with the US that may include harmful provisions threatening India’s ability to produce and supply affordable medical products. Going by past ...

Tags Intellectual property and trade United States of AmericaIndia

Press release |

01 July 2019

MSF update on 26th round of RCEP negotiations in Melbourne, Australia

While we welcome the recent withdrawal of harmful provisions from the IP chapter of RCEP, namely patent term extensions and data exclusivity, Japan’s strong push for elevated IP enforcement measures continues to be a matter of grave ...

Tags Intellectual property and trade generic medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) India

Press release |

30 April 2019

U.S. Special 301 Report Undermines Efforts to Lower Medicine Prices Globally

Tags Intellectual property and trade hepatitis C sofosbuvir India

XDR-TB_India_Patient_Bhakti_AtulLoke_Oct2016_MSF177949_3800px

Feature story

Bhakti’s Story: Strength to Survive Drug-Resistant TB

Tags drug-resistant TBtuberculosis bedaquilinedelamanid Access Campaign: 20 Years India

Technical brief |

08 February 2019

Opposing patent application for bedaquiline formulation in India

Tags Intellectual property and tradeTuberculosis drug-resistant TBtuberculosis bedaquiline patent opposition India

Video |

08 February 2019

TB survivors challenge J&J's patent on TB drug in India

Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB. Now they’re working to ensure that this doesn’t happen to anyone else.

Tags Tuberculosis bedaquiline patent opposition Johnson & Johnson India

Press release |

07 February 2019

TB activists for first time challenge TB drug patent in India

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug ...

Tags Tuberculosis drug-resistant TBtuberculosis bedaquiline Johnson & Johnson India

Video |

03 December 2018

Nursing kala azar-HIV co-infected patients in Patna, Bihar

Tags HIV/AIDSTropical & neglected diseases visceral leishmaniasis (kala azar) India

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

MSF response to signing of EFTA-India trade agreement

MSF Comments on intellectual property provisions in the final agreement of India-EFTA Agreement

MSF welcomes Indian government standing strong against EFTA trade deal’s harmful intellectual property provisions

Millions of peoples’ access to affordable medicines at risk if India-EFTA trade deal finalised as is

MSF applauds Indian Patent Office’s rejection of J&J’s attempt to extend monopoly on lifesaving TB drug

News Update: EU-India FTA negotiations could have negative impact on access to medicines

India must reject Johnson & Johnson’s attempt to extend monopoly on lifesaving TB drug bedaquiline

MSF responds to UK's disastrous proposal on intellectual property in UK-India Free Trade Agreement

MSF responds to USTR 2020 Special 301 Report

MSF submission to USTR 2020 Special 301 Report review process

World Antibiotic Awareness Week: Lack of access

Nandita Venkatesan's speech at the 50th Union World Conference on Lung Health

MSF urges PM Modi not to make any trade commitments to US threatening access to medicines

MSF update on 26th round of RCEP negotiations in Melbourne, Australia

U.S. Special 301 Report Undermines Efforts to Lower Medicine Prices Globally

Bhakti’s Story: Strength to Survive Drug-Resistant TB

Opposing patent application for bedaquiline formulation in India

TB survivors challenge J&J's patent on TB drug in India

TB activists for first time challenge TB drug patent in India

Nursing kala azar-HIV co-infected patients in Patna, Bihar